Liver Disease Treatment Secures FDA Approval For This Health Company

Chemomab Therapeutics Earns FDA Fast Track Designation for CM-101 in the Fight Against Primary Sclerosing Cholangitis.

In a significant development, Chemomab Therapeutics Ltd. has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its leading drug candidate, CM-101, in treating Primary Sclerosing Cholangitis (PSC), a rare, progressive, and chronic liver disease. This breakthrough marks a major milestone in the scientific community's ong…